SUBSCRIBERS
Amgen's new cholesterol drug falls short as sales driver
Biotech giant is anxious for Repatha to make up for slowing sales of older ones
Add BT as a preferred sourcePublished Thu, Apr 27, 2017 · 09:50 PM
San Francisco
AMGEN Inc's new cholesterol drug is still struggling to gain traction, missing analysts' estimates at a time when the biotechnology giant is anxious for its newer drugs to make up for slowing sales of its older ones.
Sales of the drug, called Repatha, for the first quarter were US$49 million, the company said on Wednesday.
Share with us your feedback on BT's products and services
